A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this first-in-human study of the formulation ABY-035/AFO2 is to investigate the safety, tolerability and efficacy after multiple doses in sequential escalating dose cohorts in psoriasis subjects.
Epistemonikos ID: 9c85af3603f6c4c4217a15e15126ff62fae3c36d
First added on: May 21, 2024